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Background. Combination antiretroviral therapy (cART) reduces genital tract human immunodeficiency virus
type 1 (HIV-1) load and reduces the risk of sexual transmission, but little is known about the efficacy of cART for
decreasing genital tract viral load (GTVL) and differences in sex or HIV-1 subtype.
Methods. HIV-1 RNA from blood plasma, seminal plasma, or cervical wicks was quantified at baseline and at
weeks 48 and 96 after entry in a randomized clinical trial of 3 cART regimens.
Results. One hundred fifty-eight men and 170 women from 7 countries were studied (men: 55% subtype B and
45% subtype C; women: 24% subtype B and 76% subtype C). Despite similar baseline CD4+ cell counts and blood
plasma viral loads, women with subtype C had the highest GTVL (median, 5.1 log10 copies/mL) compared to
women with subtype B and men with subtype C or B (4.0, 4.0, and 3.8 log10 copies/mL, respectively; P < .001). The
proportion of participants with a GTVL below the lower limit of quantification (LLQ) at week 48 (90%) and week
96 (90%) was increased compared to baseline (16%; P < .001 at both times). Women were significantly less likely to
have GTVL below the LLQ compared to men (84% vs 94% at week 48, P = .006; 84% vs 97% at week 96, P = .002),
despite a more sensitive assay for seminal plasma than for cervical wicks. No difference in GTVL response across
the 3 cART regimens was detected.
Conclusions. The female genital tract may serve as a reservoir of persistent HIV-1 replication during cART and
affect the use of cART to prevent sexual and perinatal transmission of HIV-1.
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Blood plasma and genital tract human immunodefi-
ciency virus type 1 (HIV-1) RNA concentrations are
predictors of risk for heterosexual [1, 2] and perinatal
HIV-1 transmission [3–5], and differences in blood
plasma viral load (BPVL) between men and women
with similar CD4+ cell counts have been observed [6–
11]. It is unknown whether there are sex-related differ-
ences in genital tract viral load (GTVL), because few
clinical trials in which GTVL has been measured have
enrolled sufficient numbers of both men and women.
Some studies have suggested, however, that women are
less likely to durably suppress GTVL compared to men
[12, 13]. This may be related to known differences in
antiretroviral (ART) penetration found between men
and women and among different specific ART drugs
[14, 15] or to differences in coinfections or the immu-
nologic milieu between men and women (reviewed
in [16]). Blood and seminal plasma (SP) viral loads
(VLs) may be higher with HIV-1 subtype C infection
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compared with other subtypes [17–20] and might, in part,
explain the rapid spread of HIV-1 in areas of the world where
subtype C predominates. The effect of antiretroviral therapy on
GTVL of different HIV-1 subtypes is unknown.
MATERIALS AND PARTICIPANTS
The AIDS Clinical Trials Group (ACTG) study A5185s was a
substudy of the A5175, PEARLS Trial (Prospective Evaluation
of Anti-retroviral Combinations for Treatment Naive, HIV In-
fected Persons in Resource-Limited Settings; ClinicalTrials.gov
NCT00084136) [21]. Antiretroviral-naive participants with
CD4+ lymphocytes <300/μL were randomly assigned (1:1:1) to
1 of 3 open-label combination antiretroviral (cART) regimens:
efavirenz plus co-formulated lamivudine-zidovudine (EFV +
3TC/ZDV); or atazanavir plus didanosine EC plus emtricita-
bine (ATV +DDI + FTC); or efavirenz plus co-formulated em-
tricitabine-tenofovir DF (EFV + FTC/TDF). All participants
meeting the entry criteria for PEARLS at participating sites
were offered enrollment to A5185s and provided separate in-
formed consent. A5185s was designed to evaluate differences in
GTVL between men and women and between HIV-1 subtypes
B and C, as well as the effect of cART on GTVL.
Specimen Collection and Processing
Genital secretions and blood plasma specimens were obtained
at study entry and at weeks 48 and 96. For men, semen was col-
lected at the clinic or within 2 hours prior to the clinic visit by
masturbation following a prescribed abstinence of 48 hours.
Following liquefaction, the total semen volume was determined
and the sample centrifuged at 600g for 15 minutes. For women,
a pelvic examination was performed with collection of 2 endo-
cervical wicks (Tear-Flo Diagnostic Test Strip, Odyssey, Bart-
lett, TN). Each wick was cut at the “15” mark and the 2 distal
round ends, which delivered 12 μL each, were placed into a 2-
mL cryovial containing 500 μL of NASBA Buffer solution (bio-
Mérieux, Durham, NC) and stored at −70°C. Women refrained
from any kind of sexual activity, douching, or insertion of intra-
vaginal products for at least 48 hours prior to the collection of
cervical specimens. Genital specimens were processed within 4
hours of collection and stored at −70°C. Specimens were
shipped to the University of Washington ACTG Virology Spe-
cialty Laboratory, Seattle, for HIV-1 RNA quantification.
Laboratory Testing
Blood plasma HIV-1 RNA and CD4+ cell counts were mea-
sured in PEARLS [21]. HIV-1 RNA was extracted from SP or
cervical wicks (CWs) and quantified using an independently
validated in-house real-time polymerase chain reaction assay,
with a lower limit of quantification (LLQ) of 120 copies/mL (SP)
and 1575 copies/mL (CW) and an upper limit of quantification
of 5 000 000 (SP) and 52 500 000 copies/mL (CW). The diffe-
rence in the LLQ between SP and CW was due to the require-
ment for sample dilution during specimen processing. We did
not control for HIV-1 DNA; the assay precision was <0.24
log10 nucleic acid copies/mL for genital specimens from men
and women [22, 23].
HIV-1 subtype was determined by DNA sequence analysis
of reverse transcriptase and protease in 103 participants who
were also included in a case-cohort study of virologic failures in
the main study (S. Eshleman, unpublished observations). Of
these, 29 had HIV-1 subtype B, 71 had C, 2 had F1, and 1 had
R12. All 71 participants infected with subtype C were from a
subtype C–dominant country, whereas 91% (29/32) of partici-
pants from a subtype B–dominant country were infected with
subtype B. For the remaining 228 participants in the A5185s
substudy, HIV-1 subtype was imputed using the dominant
subtype in the country where the participant was enrolled.
Overall, this resulted in 128 participants with subtype B, 200
with subtype C, and 3 with neither subtype C or B; the latter 3
were excluded from all analyses.
Statistical Analyses
Baseline characteristics were compared among the 4 sex/
subtype groups using the Wilcoxon rank-sum test for continu-
ous variables and the χ2 test for categorical variables. The
Spearman correlation was used to measure the association
between GTVL and BPVL. A median regression model was
used to compare baseline GTVL among sex/subtype groups by
including main effects for sex and subtype as well as an interac-
tion term for sex and subtype. The model was extended by in-
cluding BPVL as a covariate to assess the association between
GTVL and BPVL, and by also adding age and presence of a sex-
ually transmitted infection (STI) to evaluate whether the inter-
action of sex and subtype persisted when adjusted for BPVL,
age, and proportion with an STI. Change in the proportion of
women with VL below the LLQ from baseline to weeks 48 and
96 was evaluated using the McNemar test. Logistic regression
was used to evaluate differences according to sex/subtype and
among randomized treatments at weeks 48 and 96 in the pro-
portion of participants with GTVL below the LLQ.
RESULTS
Baseline Characteristics
Between May 2005 and November 2006, 328 individuals (158
men and 170 women; 128 infected with HIV subtype B and
200 with subtype C) of the 1571 (21%) total PEARLS partici-
pants enrolled in A5185s and provided baseline genital secre-
tions. Participants were from 16 sites in 7 countries. The
distribution of men and women varied across countries. Enroll-
ment in Brazil, India, Peru, and the United States included
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more men than women, whereas enrollment in the African
countries included more women than men (Table 1). Thus,
men were predominantly enrolled in countries in which the
dominant subtype is B and women in countries in which the
dominant subtype is C. Among men, 87 (55%) had subtype B
and 71 (45%) had subtype C, whereas among women, 41 (24%)
had subtype B and 129 (76%) had subtype C (Table 1). Selected
baseline characteristics of participants for each subtype by sex
are shown in Table 1.
The median age for participants in the substudy was 33 years
(25th–75th percentiles, 28–39 years; Table 1), varying between
32 and 33 years for women with subtypes C and B, to 34 for





B (n = 87)
Male
Subtype








(N = 328) P Value
Age, y
Median 34 34 33 32 33 .0682a
Q1, Q3 29, 42 30, 40 27, 40 27, 37 28, 39
Country
Brazil 40 (46%) 0 (0%) 12 (29%) 0 (0%) 52 (16%) <.0001b
India 0 (0%) 19 (27%) 0 (0%) 9 (7%) 28 (9%)
Malawi 0 (0%) 36 (51%) 0 (0%) 82 (64%) 118
(36%)
Peru 26 (30%) 0 (0%) 19 (46%) 0 (0%) 45 (14%)
South Africa 0 (0%) 11 (15%) 0 (0%) 27 (21%) 38 (12%)
United States 21 (24%) 0 (0%) 10 (24%) 0 (0%) 31 (9%)
Zimbabwe 0 (0%) 5 (7%) 0 (0%) 11 (9%) 16 (5%)
Screening CD4+ count,
cells/mm3
Median 196 189 171 193 193 .9002a
Q1, Q3 90, 259 121, 248 121, 234 133, 237 123, 243
Plasma HIV-1 viral load, log10 copies/mL
Median 5.0 5.0 4.9 4.9 4.9 .1722a
Q1, Q3 4.5, 5.4 4.6, 5.5 4.5, 5.3 4.5, 5.2 4.5, 5.3
Genital secretion HIV-1 viral
load, log10 copies/mL
Median 3.8 4.0 4.0 5.1 4.4 <.0001a
Q1, Q3 2.7, 4.7 3.0, 4.8 3.2, 4.9 4.4, 5.5 3.4, 5.2
Sexually transmitted
infection
Yes 30 (34%) 0 (0%) 7 (17%) 4 (3%) 41 (13%) <.0001b
No 57 (66%) 71
(100%)




ZDV/3TC + EFV 21 (24%) 26 (37%) 12 (29%) 42 (33%) 101
(31%)
.3166b
DDI + FTC +ATV 30 (34%) 26 (37%) 18 (44%) 40 (31%) 114
(35%)
TDF/FTC + EFV 36 (41%) 19 (27%) 11 (27%) 47 (36%) 113
(34%)
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men with either subtype (P = .068). The median screening
CD4+ cell count was 193 cells/μL (25th–75th percentiles, 123–
243 cells/μL; Table 1) with no significant difference among the
4 sex/subtype groups (P = .90). The median baseline blood
plasma HIV-1 RNA was 4.9 (25th–75th percentiles, 4.5–5.3)
log10 copies/mL, also with no significant difference among
the 4 sex/subtype groups (P = .17).
The proportion of participants with STIs reported at baseline
also varied significantly among the 4 sex/subtype groups
(P < .0001), reflecting higher prevalence among participants
with subtype B (34% for men and 17% for women) than
subtype C (0% for men and 3% for women). Among the 328
participants with complete baseline GTVL, there were 50 STIs
reported among 41 participants (30 males with subtype B, 7
females with subtype B, and 4 females with subtype C). Of these
50 events, 19 were syphilis, 15 were genital warts, 11 were gonor-
rhea, 2 were trichomoniasis, 2 were unspecified venereal disease,
and 1 was chlamydial infection. There was no significant diffe-
rence in baseline GTVL between those with and without STIs
(P = .107). These results, however, should be interpreted with
caution given the small number of female participants with STIs.
Baseline GTVL by Subtype and Sex
HIV-1 RNA was detected in 99% of baseline blood samples,
but in only 82% of SP samples and 86% of CW samples. The
correlation of baseline BPVL and GTVL was 0.38 for men and
0.27 for women (P < .001 for both). There was no evidence that
the association between GTVL and BPVL varied by sex or
subtype; in regression analysis, median GTVL increased by
0.58 log10 copies/mL for each 1 log10 copies/mL increase in
BPVL (95% confidence interval [CI], .38–.77 log10 copies/mL).
There was a significant difference in GTVL among the 4 sex/
subtype groups (P < .001; Table 1). Women with subtype C had
the highest median GTVL (5.1 log10 copies/mL) whereas women
with subtype B and men with subtype C or B had similar
median GTVL (4.0, 4.0, and 3.8 log10 copies/mL, respectively).
The difference in median GTVL between men and women
varied significantly according to subtype (sex by subtype interac-
tion P = .030). The estimated difference between men and
women with subtype B was not significant (difference in
medians: 0.27 log10 copies/mL higher for women; 95% CI, −.34
to .88; P = .38), whereas there was a significant difference
between men and women with subtype C (1.03 log10 copies/mL
higher for women; 95% CI, .77–1.29; P < .001). The higher
GTVL for subtype C was not driven by one particular country:
the median GTVL for men and for women with subtype C was
4.0 and 5.1 log10 copies/mL in Malawi, 4.0 and 5.0 log10 copies/
mL in South Africa, 4.1 and 5.4 log10 copies/mL in India, and
4.8 and 5.0 log10 copies/mL in Zimbabwe. The difference in
median GTVL according to sex/subtype persisted in analysis ad-
justed by BPVL, age, and STI at baseline (interaction P = .037),
and so was not explained by the observed differences in BPVL,
age, and proportion with an STI according to sex/subtype.
Effect of cART on GTVL
Among the 328 participants with baseline GTVL measurements,
40 (12%; 17 men and 23 women) were lost to follow-up or died
before 96 weeks of follow-up. A total of 269 participants (82%;
Figure 1. Proportion of participants with genital tract and blood plasma human immunodeficiency virus type 1 (HIV-1) RNA levels below the assay lower
limit of quantification by weeks after starting antiretroviral therapy by sex/HIV-1 subtype. Abbreviations: HIV-1, human immunodeficiency virus type 1; LLQ,
lower limit of quantification.
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142 men and 127 women) had evaluable results at week 48, and
250 participants (76%; 126 men and 124 women) had results at
week 96. Two hundred twenty-nine participants (70%; 122 men
and 107 women) had results at all 3 time points.
Overall, 52 (16%) of the substudy participants had GTVL
below the assay LLQ (120 copies/mL for men and 1575 copies/
mL for women) at baseline. Of the 87 and 71 men with sub-
types B and C, 17 (20%) and 11 (15%) had a baseline GTVL
below the LLQ (P = .51), and the corresponding figures for the
41 and 129 women with subtypes B and C were 12 (29%) and
12 (9%), respectively (P = .001; Figure 1).
The proportion of participants with a GTVL below the LLQ
at week 48 (90%) and week 96 (90%) was significantly increased
compared to baseline (P < .001 at both times). However,
women were significantly less likely than men to have GTVL
below the LLQ at both times despite the fact that the LLQ for
CW samples was >10 times higher than that for SP samples.
There was no evidence that the difference between men and
women varied by subtype (interaction P = .83 and P = .68 at
weeks 48 and 96, respectively). Specifically, at week 48, 84% of
women and 94% of men had GTVL below the LLQ (P = .006
comparing women to men, adjusted for subtype; Figure 1). The
corresponding proportions at week 96 were 84% and 97%
(P = .002). In contrast, only 2 (1%) had a BPVL below the assay
LLQ (400 copies/mL) at baseline. For weeks 48 and 96, 91%
and 93%, respectively, of participants had BPVL below the
LLQ with similar results in each of the 4 sex/subtype groups
(Figure 1). There was no significant difference among the 3
treatment groups in the proportion of participants with GTVL
below the LLQ at week 48 (P = .57) or week 96 (P = .73) (data
not shown).
Effect of Hormonal Contraception
Information on hormonal contraception was available for 168
women. At baseline, 30 women (18%) had been on hormonal
contraception for at least 14 days, primarily on medroxyprogester-
one (73%). The median GTVL among these women was 5.0
log10 copies/mL compared with 4.9 log10 copies/mL among
women not on hormonal contraception or on hormonal contra-
ception for <14 days (P = .49). There was no evidence that the dif-
ference between these 2 groups depended on HIV-1 subtype
(interaction P = .30). There were also no significant differences in
median age, baseline CD4 count, or baseline BPVL between these
2 groups. At weeks 48 and 96, the proportion of women on hor-
monal contraception had increased to 63% and 69%, respectively,
with about three-quarters of these on medroxyprogesterone. At
weeks 48 and 96, 84% (67 of 80 and 71 of 85, respectively) of
women on hormonal contraception had GTVL less than the LLQ
compared with 85% (39 of 46 and 33 of 39, respectively) not on
hormonal contraception (P = .88 at both times).
DISCUSSION
This study demonstrates that despite similar BPVL between
men and women and between HIV subtypes B and C, GTVLs
were significantly higher at baseline in women infected with
subtype C compared to women infected with subtype B and
men infected with either subtype. The relationship between
GTVL and subtype among women was not associated with
hormonal contraception use or STIs, and women with either
subtype were significantly less likely to have GTVL below the
LLQ at weeks 48 and 96.
In a study of early HIV infection in 188 women, Morrison
et al [19] found that Zimbabwean (subtype C) infection was asso-
ciated with increased cervical VLs compared to Ugandan women
infected with subtypes A or C. Women infected with subtype D
also had increased cervical VLs, but this was not significant [19].
However, VLs in these women were much lower (mean cervical
HIV RNA= 1.64 log10 copies/mL) compared to those observed
in this study (mean female GTVL = 4.79 log10 copies/mL).
In a large study of heterosexual HIV-1–serodiscordant
couples from 7 African countries (n = 2521) with median CD4+
cell count of 496, median endocervical VLs of 3.20 log10
copies/mL (n = 1805) and 2.57 log10 copies/mL in SP (n = 716)
were reported by Baeten et al [24]. These values are much lower
than those observed in our study (median female GTVL, 4.92
log10 copies/mL; median SP VL, 3.91 log10 copies/mL). Addi-
tionally, although the same laboratory tested genital secretions
from both Baeten et al and this study, sampling techniques for
the women differed.
Antiretrovirals were very effective in decreasing VLs in both
compartments in all participants. At weeks 48 and 96, 89% and
90%, respectively, of all participants had BPVLs that were below
the limit of quantification. However, in this study, men were sig-
nificantly more apt to have a GTVL that was below the limit of
quantitation, regardless of subtype and in spite of the difference
in the LLQ of the assay for SP (120 copies/mL) compared to the
female genital tract (1575 copies/mL). Similar results have been
reported previously [12, 13]. Differences in genital tract drug
penetration between men and women [14, 15]might explain this
finding. Of the drugs used in the study, TDF, 3TC, FTC, DDI,
and ZDV have higher seminal plasma-to-blood plasma ratios
whereas levels of EFV and ATV are negligible. In women, FTC,
3TC, and ZDV accumulate in the genital tract, whereas ATV and
EFV have lower levels in the genital tract than in blood. Blood
plasma to cervical secretion ratios for DDI and TDF have varied
[15]. The 3 randomized treatment groups had comparable pro-
portions of participants with VLs that were below the limit of
quantification both at weeks 48 and 96.
Recently, Cohen et al [25] reported that early initiation of
ART reduces the rate of sexual transmission in people with a
CD4+ cell count between 350 and 550 cells/µL. Baeten et al [24]
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observed that genital HIV RNA independently predicted trans-
mission after adjusting for BPVL. In the absence of ART, 59%–
67% of the genetically linked transmissions in these 2 studies
have been from women to men. Because participants in our
study were more immunocompromised (median CD4+ cell
count, 194) and GTVL was 1.3–1.7 log10 copies/mL greater
than those in the Baeten et al study, the risks for sexual trans-
mission are presumably greater in the absence of cART.
The strengths of the present study are the relatively large
number of participants from ethnically and geographically
diverse areas of the world infected with different HIV-1 sub-
types. These locations coincide with all but 2 of the sites where
PEARLS was conducted and with 6 of 13 HPTN 052 sites [25].
However, A5185s study participants had <300 CD4 cells/μL at
entry and are thus more representative of individuals starting
antiretrovirals under current World Health Organization treat-
ment guidelines. The same laboratory performed the genital
tract HIV RNA assays for the Partners in Prevention HSV/HIV
Transmission Study [25], minimizing one potential confounder
when trying to make comparisons between studies.
Our study has several important limitations. Participation in
A5185s was voluntary and, as a consequence, there may be
some selection bias. Assignment of subtype for 69% of the par-
ticipants was based on country of residence, and there may
have been some misclassification. However, we think the likeli-
hood of misclassification is small, as all participating countries
except Brazil have a dominant subtype comprising 96%–100%
of the sequences for that country [26]. Additionally, there was a
nonrandom distribution of HIV subtypes between men and
women, and the differences observed were largely driven by the
higher GTVL observed in women infected with subtype C from
all countries. There were differences in the lower limit of detec-
tion of the GTVL assays, although that does not explain the sig-
nificantly higher GTVL observed in women. We did not
measure or control for HIV proviral DNA, which might have
contributed to the higher GTVL found in women. Although
GTVL can be affected by STIs and bacterial vaginosis, few STIs
were recorded and information on bacterial vaginosis was not
collected. Unmeasured coinfections and inflammation in
women may have led to higher GTVL measurements.
In summary, we have demonstrated that GTVL differs ac-
cording to sex and HIV subtype, with higher levels in women
with subtype C virus. Moreover, women are less likely to sup-
press GTVL after initiating cART. The female genital tract may
serve as a reservoir of persistent HIV-1 replication during
cART and affect the use of cART to prevent sexual and perina-
tal transmission of HIV-1.
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